

Dr. Vinay Chopra
 MD (Pathology & Microbiology)
 Chairman & Consultant Pathologist

Dr. Yugam Chopra
 MD (Pathology)
 CEO & Consultant Pathologist

| | | | |
|-----------------------|--|--------------------------|------------------------|
| NAME | : Miss. JASMINE KAUR | PATIENT ID | : 1574034 |
| AGE/ GENDER | : 27 YRS/FEMALE | REG. NO./LAB NO. | : 012408070048 |
| COLLECTED BY | : SURJESH | REGISTRATION DATE | : 07/Aug/2024 06:11 PM |
| REFERRED BY | : | COLLECTION DATE | : 07/Aug/2024 06:17PM |
| BARCODE NO. | : 01514669 | REPORTING DATE | : 07/Aug/2024 07:22PM |
| CLIENT CODE. | : KOS DIAGNOSTIC LAB | | |
| CLIENT ADDRESS | : 6349/1, NICHOLSON ROAD, AMBALA CANTT | | |

| Test Name | Value | Unit | Biological Reference interval |
|-----------|-------|------|-------------------------------|
|-----------|-------|------|-------------------------------|

ENDOCRINOLOGY

THYROID FUNCTION TEST: TOTAL

| | | | |
|--|-------|--------|--------------|
| TRIIODOTHYRONINE (T3): SERUM | 0.863 | ng/mL | 0.35 - 1.93 |
| by CMIA (CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY) | | | |
| THYROXINE (T4): SERUM | 6.31 | µgm/dL | 4.87 - 12.60 |
| by CMIA (CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY) | | | |
| THYROID STIMULATING HORMONE (TSH): SERUM | 3.057 | µIU/mL | 0.35 - 5.50 |
| by CMIA (CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY) | | | |

3rd GENERATION, ULTRA SENSITIVE

INTERPRETATION:

TSH levels are subject to circadian variation, reaching peak levels between 2-4 a.m and at a minimum between 6-10 pm. The variation is of the order of 50%. Hence time of the day has influence on the measured serum TSH concentrations. TSH stimulates the production and secretion of the metabolically active hormones, thyroxine (T4) and triiodothyronine (T3). Failure at any level of regulation of the hypothalamic-pituitary-thyroid axis will result in either underproduction (hypothyroidism) or overproduction (hyperthyroidism) of T4 and/or T3.

| CLINICAL CONDITION | T3 | T4 | TSH |
|------------------------------|-----------------------|-----------------------|---------------------------------|
| Primary Hypothyroidism: | Reduced | Reduced | Increased (Significantly) |
| Subclinical Hypothyroidism: | Normal or Low Normal | Normal or Low Normal | High |
| Primary Hyperthyroidism: | Increased | Increased | Reduced (at times undetectable) |
| Subclinical Hyperthyroidism: | Normal or High Normal | Normal or High Normal | Reduced |

LIMITATIONS:-

- T3 and T4 circulates in reversibly bound form with Thyroid binding globulins (TBG), and to a lesser extent albumin and Thyroid binding Pre Albumin so conditions in which TBG and protein levels alter such as pregnancy, excess estrogens, androgens, anabolic steroids and glucocorticoids may falsely affect the T3 and T4 levels and may cause false thyroid values for thyroid function tests.
- Normal levels of T4 can also be seen in Hyperthyroid patients with :T3 Thyrotoxicosis, Decreased binding capacity due to hypoproteinemia or ingestion of certain drugs (eg: phenytoin, salicylates).
- Serum T4 levels in neonates and infants are higher than values in the normal adult, due to the increased concentration of TBG in neonate serum.
- TSH may be normal in central hypothyroidism, recent rapid correction of hyperthyroidism or hypothyroidism, pregnancy, phenytoin therapy.

| TRIIODOTHYRONINE (T3) | | THYROXINE (T4) | | THYROID STIMULATING HORMONE (TSH) | |
|-----------------------|--------------------------|-------------------|--------------------------|-----------------------------------|--------------------------|
| Age | Refferance Range (ng/mL) | Age | Refferance Range (µg/dL) | Age | Reference Range (µIU/mL) |
| 0 - 7 Days | 0.20 - 2.65 | 0 - 7 Days | 5.90 - 18.58 | 0 - 7 Days | 2.43 - 24.3 |
| 7 Days - 3 Months | 0.36 - 2.59 | 7 Days - 3 Months | 6.39 - 17.66 | 7 Days - 3 Months | 0.58 - 11.00 |
| 3 - 6 Months | 0.51 - 2.52 | 3 - 6 Months | 6.75 - 17.04 | 3 Days - 6 Months | 0.70 - 8.40 |




DR. VINAY CHOPRA
 CONSULTANT PATHOLOGIST
 MBBS, MD (PATHOLOGY & MICROBIOLOGY)


DR. YUGAM CHOPRA
 CONSULTANT PATHOLOGIST
 MBBS, MD (PATHOLOGY)



Dr. Vinay Chopra
 MD (Pathology & Microbiology)
 Chairman & Consultant Pathologist

Dr. Yugam Chopra
 MD (Pathology)
 CEO & Consultant Pathologist

| | | | |
|-----------------------|--|--------------------------|------------------------|
| NAME | : Miss. JASMINE KAUR | PATIENT ID | : 1574034 |
| AGE/ GENDER | : 27 YRS/FEMALE | REG. NO./LAB NO. | : 012408070048 |
| COLLECTED BY | : SURJESH | REGISTRATION DATE | : 07/Aug/2024 06:11 PM |
| REFERRED BY | : | COLLECTION DATE | : 07/Aug/2024 06:17PM |
| BARCODE NO. | : 01514669 | REPORTING DATE | : 07/Aug/2024 07:22PM |
| CLIENT CODE. | : KOS DIAGNOSTIC LAB | | |
| CLIENT ADDRESS | : 6349/1, NICHOLSON ROAD, AMBALA CANTT | | |

| Test Name | Value | Unit | Biological Reference interval |
|--|-------------|---------------------|-------------------------------|
| 6 - 12 Months | 0.74 - 2.40 | 6 - 12 Months | 7.10 - 16.16 |
| 1 - 10 Years | 0.92 - 2.28 | 1 - 10 Years | 6.00 - 13.80 |
| 11- 19 Years | 0.35 - 1.93 | 11 - 19 Years | 4.87- 13.20 |
| > 20 years (Adults) | 0.35 - 1.93 | > 20 Years (Adults) | 4.87 - 12.60 |
| RECOMMENDATIONS OF TSH LEVELS DURING PREGNANCY (μ U/mL) | | | |
| 1st Trimester | | | 0.10 - 2.50 |
| 2nd Trimester | | | 0.20 - 3.00 |
| 3rd Trimester | | | 0.30 - 4.10 |

INCREASED TSH LEVELS:

- 1.Primary or untreated hypothyroidism may vary from 3 times to more than 100 times normal depending upon degree of hypofunction.
- 2.Hypothyroid patients receiving insufficient thyroid replacement therapy.
- 3.Hashimotos thyroiditis
- 4.DRUGS: Amphetamines, idonie containing agents & dopamine antagonist.
- 5.Neonatal period, increase in 1st 2-3 days of life due to post-natal surge

DECREASED TSH LEVELS:

- 1.Toxic multi-nodular goitre & Thyroiditis.
- 2.Over replacement of thyroid hormone in treatment of hypothyroidism.
- 3.Autonomously functioning Thyroid adenoma
- 4.Secondary pituitary or hypothalamic hypothyroidism
- 5.Acute psychiatric illness
- 6.Severe dehydration.
- 7.DRUGS: Glucocorticoids, Dopamine, Levodopa, T4 replacement therapy, Anti-thyroid drugs for thyrotoxicosis.
- 8.Pregnancy: 1st and 2nd Trimester




DR.VINAY CHOPRA
 CONSULTANT PATHOLOGIST
 MBBS, MD (PATHOLOGY & MICROBIOLOGY)


DR.YUGAM CHOPRA
 CONSULTANT PATHOLOGIST
 MBBS, MD (PATHOLOGY)



Dr. Vinay Chopra
 MD (Pathology & Microbiology)
 Chairman & Consultant Pathologist

Dr. Yugam Chopra
 MD (Pathology)
 CEO & Consultant Pathologist

| | | | |
|-----------------------|--|--------------------------|------------------------|
| NAME | : Miss. JASMINE KAUR | PATIENT ID | : 1574034 |
| AGE/ GENDER | : 27 YRS/FEMALE | REG. NO./LAB NO. | : 012408070048 |
| COLLECTED BY | : SURJESH | REGISTRATION DATE | : 07/Aug/2024 06:11 PM |
| REFERRED BY | : | COLLECTION DATE | : 07/Aug/2024 06:17PM |
| BARCODE NO. | : 01514669 | REPORTING DATE | : 07/Aug/2024 07:22PM |
| CLIENT CODE. | : KOS DIAGNOSTIC LAB | | |
| CLIENT ADDRESS | : 6349/1, NICHOLSON ROAD, AMBALA CANTT | | |

| Test Name | Value | Unit | Biological Reference interval |
|-----------|-------|------|-------------------------------|
|-----------|-------|------|-------------------------------|

VITAMINS

VITAMIN D/25 HYDROXY VITAMIN D3

VITAMIN D (25-HYDROXY VITAMIN D3): SERUM
 by CLIA (CHEMILUMINESCENCE IMMUNOASSAY)

21.425^L

ng/mL

DEFICIENCY: < 20.0
INSUFFICIENCY: 20.0 - 30.0
SUFFICIENCY: 30.0 - 100.0
TOXICITY: > 100.0

INTERPRETATION:

| | | |
|------------------|----------|-------|
| DEFICIENT: | < 20 | ng/mL |
| INSUFFICIENT: | 21 - 29 | ng/mL |
| PREFERRED RANGE: | 30 - 100 | ng/mL |
| INTOXICATION: | > 100 | ng/mL |

1. Vitamin D compounds are derived from dietary ergocalciferol (from plants, Vitamin D2), or cholecalciferol (from animals, Vitamin D3), or by conversion of 7- dihydrocholecalciferol to Vitamin D3 in the skin upon Ultraviolet exposure.
2. 25-OH--Vitamin D represents the main body reservoir and transport form of Vitamin D and transport form of Vitamin D, being stored in adipose tissue and tightly bound by a transport protein while in circulation.
3. Vitamin D plays a primary role in the maintenance of calcium homeostasis. It promotes calcium absorption, renal calcium absorption and phosphate reabsorption, skeletal calcium deposition, calcium mobilization, mainly regulated by parathyroid hormone (PTH).
4. Severe deficiency may lead to failure to mineralize newly formed osteoid in bone, resulting in rickets in children and osteomalacia in adults.

DECREASED:

1. Lack of sunshine exposure.
2. Inadequate intake, malabsorption (celiac disease)
3. Depressed Hepatic Vitamin D 25- hydroxylase activity
4. Secondary to advanced Liver disease
5. Osteoporosis and Secondary Hyperparathyroidism (Mild to Moderate deficiency)
6. Enzyme Inducing drugs: anti-epileptic drugs like phenytoin, phenobarbital and carbamazepine, that increases Vitamin D metabolism.

INCREASED:

1. Hypervitaminosis D is Rare, and is seen only after prolonged exposure to extremely high doses of Vitamin D. When it occurs, it can result in severe hypercalcemia and hyperphosphatemia.

CAUTION: Replacement therapy in deficient individuals must be monitored by periodic assessment of Vitamin D levels in order to prevent hypervitaminosis D

NOTE:- Dark coloured individuals as compare to whites, is at higher risk of developing Vitamin D deficiency due to excess of melanin pigment which interfere with Vitamin D absorption.

*** End Of Report ***





DR. VINAY CHOPRA
 CONSULTANT PATHOLOGIST
 MBBS, MD (PATHOLOGY & MICROBIOLOGY)



DR. YUGAM CHOPRA
 CONSULTANT PATHOLOGIST
 MBBS, MD (PATHOLOGY)

